Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lutathera is a prescription radiolabeled somatostatin analog containing lutetium Lu 177 dotatate. It is indicated for adults and pediatric patients age 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. These include qualifying foregut, midgut, and hindgut neuroendocrine tumors.
read more about lutathera ...Lutetium Lu 177 dotatate binds to somatostatin receptors, particularly subtype 2, on susceptible neuroendocrine tumor cells. After binding and cellular uptake, lutetium-177 emits beta radiation that damages tumor-cell DNA and contributes to cell death.
Lutathera is used in adults and children age 12 and older with gastroenteropancreatic neuroendocrine tumors that demonstrate somatostatin receptor positivity. Treatment is administered by clinicians trained to handle radioactive medicines. Blood counts, kidney function, and liver function are assessed before and during treatment.
The recommended dose is 7.4 GBq, equivalent to 200 mCi, by intravenous infusion every eight weeks for four doses. Patients receive antiemetics and an intravenous amino acid infusion to reduce radiation exposure to the kidneys. Long-acting octreotide 30 mg is administered intramuscularly four to 24 hours after each Lutathera dose, with continued octreotide treatment afterward according to current labeling.
Serious risks include radiation exposure, bone marrow suppression, secondary myelodysplastic syndrome or leukemia, kidney injury, liver toxicity, severe hypersensitivity, neuroendocrine hormonal crisis, infertility, and fetal harm. Long-term monitoring is necessary due to the potential for delayed radiation-related toxicity. Kidney-protective amino acid infusions and hydration are part of treatment.
Lutathera treats somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults and children age 12 and older.
The recommended dose is 7.4 GBq or 200 mCi by intravenous infusion every eight weeks for four doses.
Intravenous amino acids reduce radiation exposure to the kidneys and help limit kidney toxicity.
Yes. Lutathera can cause low blood-cell counts and has been associated with secondary myelodysplastic syndrome and leukemia.
FDA Approves Lutetium Lu 177 Dotatate for Pediatric Patients 12 Years and Older With GEP-NETs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets. Date Accessed October 13, 2026.
LUTATHERA (lutetium Lu 177 dotatate) Prescribing Information. Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/lutathera.pdf. Date Accessed October 13, 2026.
Lutetium Lu 177-Dotatate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/lutetiumlu177-dotatate. Date Accessed October 13, 2026.
Lutetium Lu 177 Dotatate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lutetium-Lu-177-Dotatate. Date Accessed October 13, 2026.
Search Orphan Drug Designations and Approvals - Lutetium Lu 177 Dotatate. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=271008. Date Accessed October 13, 2026.